Announcement • Aug 10
Optima Health plc to Report Fiscal Year 2026 Results on Aug 17, 2026 Optima Health plc announced that they will report fiscal year 2026 results at 8:00 AM, GMT Standard Time on Aug 17, 2026 Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to UK£2.30, the stock trades at a forward P/E ratio of 49275x. Average forward P/E is 22x in the Healthcare industry in the United Kingdom. Total returns to shareholders of 13% over the past year. Announcement • Jun 17
Optima Health plc Provides Earnings Guidance for the Fiscal Year Ended March 31, 2026 Optima Health plc provided earnings guidance for the fiscal year ended March 31, 2026. Optima expects to report revenue for the full year of approximately £121 million, in line with market expectations, representing 15% growth versus FY25. New Risk • Apr 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Announcement • Apr 24
Optima Health plc has completed a Follow-on Equity Offering in the amount of £34.998511 million. Optima Health plc has completed a Follow-on Equity Offering in the amount of £34.998511 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 19,951,631
Price\Range: £1.75
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 47,518
Price\Range: £1.75
Transaction Features: Rights Offering Announcement • Apr 02
Optima Health plc has filed a Follow-on Equity Offering in the amount of £34.998511 million. Optima Health plc has filed a Follow-on Equity Offering in the amount of £34.998511 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 19,999,149
Price\Range: £1.75 Announcement • Mar 23
Optima Health plc Announces Chief Financial Officer Changes Optima Health PLC announced that Heidi Giles, Chief Financial Officer, will leave the Company on July 31, 2026. Subject to the successful completion of the recently announced acquisition of PAM Healthcare, Optima will appoint Andrew Bones as Interim Chief Financial Officer. Heidi remains a director of the Company during this period, and will continue to fulfil her current role facilitating a smooth transition. Announcement • Feb 17
Optima Health plc (AIM:OPT) entered into an acquisition agreement to acquire Pam Healthcare Ltd from LDC (Managers) Limited for £100 million. Optima Health plc (AIM:OPT) entered into an acquisition agreement to acquire Pam Healthcare Ltd from LDC (Managers) Limited for £100 million on February 14, 2026. A cash consideration of £100 million on a debt-free, cash-free, normalised working capital basis, subject to customary adjustments will be paid by Optima Health plc. Once completed, the transaction will mark an exit for leading UK private equity investor, LDC. The acquisition will be financed partly through new committed secured debt facilities of £70 million with existing banking partners HSBC and Barclays and partly through an unsecured short-term related party bridge facility of £30 million with Deacon Street Partners Limited.
For the period ending December 31, 2025, Pam Healthcare Ltd reported total revenue of £66.6 million, net loss of £0.5 million and EBITDA of £6.6 million. As of December 31, 2025, Pam Healthcare Ltd reported total common equity of £21.3 million.
Completion of the Acquisition is only conditional on clearance being obtained from the Irish Foreign Direct Investment regime, which is expected to be received within 90 days of signing the Acquisition Agreement. The transaction is expected to be accretive to adjusted EPS.
Emma Earl, Will Goode, Mark Rogers, Rupert Dearden, Dan Howlett and Ben Handler Panmure Liberum Limited acted as nominated financial advisor for Optima Health plc. Buy Or Sell Opportunity • Jan 28
Now 22% undervalued Over the last 90 days, the stock has risen 9.6% to UK£2.17. The fair value is estimated to be UK£2.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 68% in the next 2 years. Reported Earnings • Dec 12
First half 2026 earnings released: EPS: UK£0.014 (vs UK£0.077 loss in 1H 2025) First half 2026 results: EPS: UK£0.014 (up from UK£0.077 loss in 1H 2025). Revenue: UK£59.5m (up 17% from 1H 2025). Net income: UK£1.20m (up UK£1.88m from 1H 2025). Profit margin: 2.0% (up from net loss in 1H 2025). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Announcement • Nov 13
Optima Health plc to Report First Half, 2026 Results on Dec 10, 2025 Optima Health plc announced that they will report first half, 2026 results on Dec 10, 2025 Buy Or Sell Opportunity • Oct 16
Now 20% undervalued Over the last 90 days, the stock has risen 17% to UK£2.27. The fair value is estimated to be UK£2.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 20% in a year. Earnings are forecast to decline by 33% in the next year. Announcement • Jul 30
Optima Health plc, Annual General Meeting, Sep 01, 2025 Optima Health plc, Annual General Meeting, Sep 01, 2025. Location: optima health, 5th floor, cornerblock, 11 quay street, manchester, m3 3hn, United Kingdom Reported Earnings • Jul 08
Full year 2025 earnings: Revenues miss analyst expectations Full year 2025 results: Revenue: UK£105.0m (down 5.3% from FY 2024). Net income: UK£1.65m (up UK£2.74m from FY 2024). Profit margin: 1.6% (up from net loss in FY 2024). Revenue missed analyst estimates by 1.0%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. New Risk • Jun 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£346k net loss next year). Announcement • Jun 05
Optima Health plc to Report Fiscal Year 2025 Results on Jul 08, 2025 Optima Health plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Jul 08, 2025 New Risk • Apr 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.5m Forecast net loss in 1 year: UK£346k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Announcement • Apr 12
Optima Health plc (AIM:OPT) entered into an agreement to acquire Cognate Health Limited for €9 million. Optima Health plc (AIM:OPT) entered into an agreement to acquire Cognate Health Limited for €9 million on April 11, 2025. A cash consideration of €7 million will be paid by Optima Health plc. Optima Health plc will pay an earnout/contingent payment of €2 million cash. As part of consideration, €9 million is paid towards common equity of Cognate Health Limited on cash free and debt free basis.
For the period ending December 31, 2024, Cognate Health Limited reported total revenue of €7.37 million. As of December 31, 2024, Cognate Health Limited reported total common equity of €1.28 million.
Emma Earl, Will Goode, Mark Rogers and Rupert Dearden of Panmure Liberum Limited acted as financial advisor for Optima Health plc. Announcement • Jan 16
Optima Health plc (AIM:OPT) entered into an agreement to acquire BHSF Occupational Health Limited from BHSF Limited for £1.4 million. Optima Health plc (AIM:OPT) entered into an agreement to acquire BHSF Occupational Health Limited from BHSF Limited for £1.4 million on January 16, 2025. Under the terms of the agreement, Optima Health will pay a total consideration of £1.4 million on completion to acquire the entire issued share capital of BHSF Occupational Health Limited on a cash free, debt free basis, subject to adjustment for normalised working capital. The Acquisition will be financed in cash using existing funds on its balance sheet.
For the period ending December 31, 2024, BHSF Occupational Health Limited reported total revenue of £8.3 million and net income of £3 million. Subject to customary closing conditions, the Acquisition is expected to complete around the end of January 2025.
Emma Earl, Will Goode, Mark Rogers and Rupert Dearden of Panmure Liberum Limited acted as financial advisor to Optima Health. Reported Earnings • Dec 12
First half 2025 earnings released First half 2025 results: UK£0.077 loss per share. Net loss: UK£672.0k (flat on 1H 2024). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare Services industry in the United Kingdom. Announcement • Nov 27
Optima Health plc to Report First Half, 2025 Results on Dec 11, 2024 Optima Health plc announced that they will report first half, 2025 results on Dec 11, 2024 
